Sign in

You're signed outSign in or to get full access.

Jeffrey Sakaguchi

Chair of the Board at TrueBlue
Board

About Jeffrey B. Sakaguchi

Jeffrey B. Sakaguchi, age 64, is the independent Chair of the Board at TrueBlue, Inc. (TBI) and has served as a director since December 2010; he became Board Chair in June 2022. He sits on the Corporate Governance & Nominating, Audit, and Innovation & Technology committees, and is designated an “audit committee financial expert.” His background includes leadership roles at Accenture and McKinsey & Company and president/COO of Evolution Robotics Retail. He is an NACD Leadership Fellow, NACD directorship-certified, and serves as an Educational Counselor for MIT. Attendance standards were met company-wide (≥75%), with the Board meeting seven times in 2024; eight of nine directors are independent. He was affirmed independent with a 14-year tenure as of March 27, 2025 .

Past Roles

OrganizationRoleTenureCommittees/Impact
Evolution Robotics Retail, Inc.President & COOSenior operating leadership; strategy and execution
AccentureLeadership rolesStrategy and management consulting expertise
McKinsey & CompanyLeadership rolesStrategy consulting; performance improvement

External Roles

OrganizationRoleTenureNotes
Eccentex, Inc. (private)DirectorCurrentEarly-stage software company
ThinkIQ, Inc. (private)DirectorPriorEarly-stage software; prior role noted in earlier proxy
ACT Holdings, Inc.Founding board memberPriorPrior role noted
Habla.AIAdvisory board memberPriorPrior role noted
Los Angeles Region American Red CrossMember, former Chair; National Philanthropic BoardOngoing/priorCommunity leadership

Board Governance

  • Leadership structure separates CEO and Board Chair (separation maintained for 20+ years); lead independent director used when the Chair is not independent. Sakaguchi serves as Board Chair and is independent, reducing need for a separate LID .
  • Committee memberships: Audit (member, designated “financial expert”), Corporate Governance & Nominating, and Innovation & Technology (all board members sit on I&T). The Audit Committee met 8 times in 2024; the Board met seven times, and all directors attended ≥75% of Board/committee meetings .
  • Independence: 8 of 9 directors are independent; Sakaguchi affirmed independent, tenure 14 years as of March 27, 2025 .
  • Executive sessions: Independent directors meet in executive session routinely without management present .
  • Shareholder votes: On May 14, 2025, shareholders re-elected all nine directors; advisory say-on-pay and the omnibus plan amendment were approved; auditor ratified (Deloitte) .

2025 Annual Meeting Vote Results

ItemForAgainstAbstainBroker Non-Votes
Director Election – Sakaguchi22,705,629 2,025,911 19,326 2,334,722
Say-on-Pay21,414,998 3,270,133 65,735 2,334,722
2016 Omnibus Plan Amendment22,836,101 1,894,801 19,964 2,334,722
Auditor Ratification (Deloitte)26,795,296 280,218 10,074

Fixed Compensation

YearFees Earned and Paid in CashStock Award Grant Date Fair ValueTotal
2024$144,500 $138,848 $283,348
2023$135,750 $172,357 $308,107
  • Cash retainer schedule (unchanged for 2025): Board Chair $122,000; other directors $77,000; committee retainers: Audit $12,500, Compensation $12,500, Governance $5,000, Innovation & Technology $5,000; committee chair supplement: $15,000 for each committee .
  • Director equity grant policy: Annual RSU grant typically on the second trading day after Q4/YE earnings; 2024 RSUs vested on September 30, 2024; beginning in 2025, RSUs vest on the one-year anniversary of grant .

Performance Compensation

  • Directors receive time-based RSUs; no performance-conditioned equity is used for directors (PSUs are used for executives). The Board Chair’s RSU target value was $175,000 in 2024; audit and compensation committee chairs received an additional $10,000 in RSUs; other committee chairs received $7,500. RSU counts are determined from a 60-trading-day average price (~$14.18) and grant-date fair value used $11.25 closing price; beginning in 2025, vesting occurs one year from grant date .
Equity Component2024 Detail
RSU Target – Board Chair$175,000
Grant-date closing price (for fair value)$11.25
Pricing basis for RSU count60-day average ≈ $14.18
Vesting2024 grants vested on 9/30/2024; 2025 grants vest 1-year from grant

Other Directorships & Interlocks

  • No current public company directorships disclosed for Sakaguchi; external board roles are private (Eccentex) and prior roles (ThinkIQ, ACT Holdings, Habla.AI). No disclosed interlocks with TBI customers/suppliers; Governance Committee oversees conflicts and related-party matters .

Expertise & Qualifications

  • Strategy, technology, and operating leadership (Accenture, McKinsey, Evolution Robotics Retail); Board Chair; audit committee financial expertise designation; NACD Leadership Fellow and directorship-certified; MIT Educational Counselor .

Equity Ownership

DateTransaction TypeShares TransactedPricePost-Transaction Ownership
2025-02-21Award (A)22,241$088,710
2024-02-23Award (A)12,342$066,469
2023-12-01Gift (G)358$054,127
2023-02-03Award (A)8,738$054,485
2022-11-29Gift (G)485$045,747
2022-02-04Award (A)6,332$046,232
2021-11-30Gift (G)381$039,900
2021-02-05Award (A)7,933$040,281
2020-12-27Form 5 (annual)
2020-02-07Award (A)6,612$032,638
  • Stock ownership guidelines for directors: raised to 5x annual cash retainer as of 2024/2025; compliance: as of end of 2024, all non-employee directors met or were on track within the allowed period. Anti-hedging is prohibited; pledging is discouraged .
  • Section 16 filings: Company disclosed minor administrative delays (including Sakaguchi’s 12/1/2023 filing made 12/6/2023) .

Governance Assessment

  • Strengths:

    • Independent Board Chair with deep strategy/technology pedigree; clear separation of CEO and Chair roles .
    • Robust committee structure; Sakaguchi designated audit committee financial expert; consistent attendance standards achieved .
    • Clear director compensation framework, majority equity, and enhanced ownership guidelines (5x retainer) improving alignment; anti-hedging/pledging discouraged .
    • No related-person transactions in 2024; strong conflict review by Governance Committee .
  • Watch items / red flags:

    • No specific director-level performance metrics (director equity is time-based RSUs); oversight relies on ownership guidelines and committee work rather than performance-conditioned equity .
    • Minor Section 16 administrative filing delays noted; not material but a process point .
  • Shareholder confidence signals:

    • Strong voting support across proposals in 2025; prior high say-on-pay support (91% in 2024) .

Director Compensation Structure Analysis

  • Mix/Trend: Directors compensated via cash retainer plus RSUs; company shifted away from options years prior (no options for directors in 2017–2019 tables; 2016 allowed but uncommon thereafter) .
  • Year-over-year: Sakaguchi’s cash fees rose from $135,750 (2023) to $144,500 (2024), while stock grant fair value moved from $172,357 (2023) to $138,848 (2024), reflecting share price changes and board grant policy .
  • Governance controls: Independent compensation consultant (Mercer) advises the Compensation Committee; director pay benchmarked and held flat for 2025 despite WTW recommendations .

Related Party Transactions and Conflicts

  • Policy mandates Governance Committee review for any transactions >$120,000 with a related person; none in 2024; directors complete annual questionnaires; anti-hedging policy in force, pledging discouraged .

Say-on-Pay & Shareholder Feedback

  • Support levels: 2024 say-on-pay approval at 91% (company-reported); 2025 meeting vote counts presented above. Compensation Committee considers investor feedback and maintains best-pay practices (clawbacks, double-trigger CIC, no re-pricing/gross-ups) .

Compensation Committee Analysis

  • Composition: All independent directors; oversight of executive compensation and HCM; independent consultant (Mercer) used; meetings 5 in 2024 .
  • Interlocks: None disclosed for 2024 .

RED FLAGS

  • None material disclosed: no related-party transactions; anti-hedging policy; pledging discouraged; director attendance standards met; strong shareholder support. Minor Section 16 timing disclosures noted .